HEK293 TLR9 NFkB-Luci Cell Line
Item | Cat# | Price |
Stable Cell Line | SNB-OT-0005 | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
Toll-like receptor 9 (TLR9) is an intracellular pattern-recognition receptor that detects unmethylated CpG motifs commonly found in bacterial and viral DNA. Localized mainly in endosomes of plasmacytoid dendritic cells, B cells, macrophages, and certain epithelial cells, TLR9 plays a critical role in initiating early immune responses against pathogens. Upon recognizing CpG-rich DNA, TLR9 triggers MyD88-dependent signaling, activating NF-κB and IRF7 pathways, which promote the production of pro-inflammatory cytokines, type I interferons, and B-cell activation signals. These responses support both innate and adaptive immunity, particularly antiviral defense. TLR9 also contributes to shaping immune tolerance and maintaining mucosal homeostasis. However, aberrant TLR9 activation or dysregulation has been linked to autoimmune diseases such as systemic lupus erythematosus, chronic inflammation, and certain cancers. Because of its strong immunostimulatory properties, TLR9 is an important therapeutic target, with CpG-based agonists being actively explored in vaccines, cancer immunotherapy, and antiviral treatments.
Screeningbio’s HEK293/TLR9/NFkB-Luciferase reporter gene cell line stable expressed TLR9 protein and NFkB response element upstream of luciferase gene. Upon stimulated by TLR ligand, NFkB pathway was activated and induce luciferase expression.
Product Specifications
Target Type | TLR9 |
Species | Human |
HGNC Symbol | TLR9 |
Accession Number | NM_017442 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
Toll-like receptor 9 (TLR9) is an endosomal DNA-sensing receptor that plays a key role in host defense, but its dysregulation is implicated in a wide range of diseases. TLR9 recognizes unmethylated CpG motifs enriched in bacterial and viral DNA, triggering MyD88-dependent activation of NF-κB and IRF pathways to induce pro-inflammatory cytokines and type I interferons. While this response is essential for antiviral and antibacterial immunity, excessive activation of TLR9 can drive pathological inflammation. In autoimmune diseases, such as systemic lupus erythematosus (SLE), psoriasis, and rheumatoid arthritis, aberrant recognition of self-DNA or immune complexes leads to chronic TLR9 stimulation, promoting autoantibody production and tissue damage. In inflammatory bowel disease (IBD), dysregulated TLR9 signaling influences mucosal inflammation and epithelial repair. TLR9 also plays a complex role in cancer: CpG-mediated activation can enhance antitumor immunity through dendritic cell maturation, yet tumor-intrinsic TLR9 signaling may support proliferation, invasion, or therapy resistance in certain malignancies. Additionally, TLR9 is implicated in asthma, chronic viral infections, metabolic disorders, and liver diseases. Because of its potent immunomodulatory effects, TLR9 is a promising therapeutic target, and CpG-based agonists or antagonists are being actively developed for vaccines, immunotherapy, and autoimmune treatment.